CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Sagar Bhosale

Reviews

SKF INDIA

Ticker : 500472
FV: Rs.10
52-Week H/L : Rs.2164.50/1610



We had recommended SKF India Ltd. in volume no. 35, issue no. 35 (dated June 24, 2019), when the scrip was trading at Rs. 1,985. SKF India Ltd. has two business segments, including sales of in-house manufactured goods and services and sales of traded goods manufactured by other related SKF companies. The company offers bearing and its components. It has business in the domestic as well as foreign markets. The stock was previously recommended due to the pick-up in the industrial performance. In Q4FY19, the company’s revenue increased by 6.37 per cent to Rs. 748.44 crore from Rs. 703.64 crore in Q4FY18. The PBDT for Q4FY19 stood at Rs. 138.33 core, an increase of 12.24 per cent as compared to Rs. 123.24 crore for Q4FY18. In Q4FY19, the net profit increased by 14.87 per cent to Rs. 82.20 crore as against Rs. 71.56 crore in Q4FY18. The company’s board of directors recommended a dividend of Rs. 12 per share. Considering the company's strong financials, we recommend a HOLD

Previous Article Fundamental
Next Article Torrent Pharma: USFDA classifies Dahej facility as OAI
Print
106 Rate this article:
No rating
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR